Hikal Limited announced its financial results for the first quarter of FY27 (ended June 30, 2026). The company reported a consolidated revenue of ₹403 crore, a growth of 6.2% year-on-year. EBITDA stood at ₹37 crore, with an EBITDA margin of 9.2%. The Pharmaceutical business saw revenue grow to ₹233 crore, while Crop Protection revenue was ₹170 crore.
Hikal Reports Q1 FY27 Financial Performance
Hikal Limited has released its financial results for the first quarter of the financial year 2027, which concluded on June 30, 2026. The company demonstrated revenue growth amidst geopolitical and macroeconomic headwinds. Consolidated revenue for the quarter stood at ₹403 crore, marking a 5.9% increase compared to ₹380 crore in Q1 FY26. The quarterly EBITDA was reported at ₹37 crore, a significant rise from ₹25 crore in the prior year’s corresponding quarter, leading to an improved EBITDA margin of 9.2% from 6.6% in Q1 FY26.
Segmental Performance Highlights
In terms of revenue split, the Pharmaceuticals segment accounted for 58% of the total revenue in Q1 FY27, with revenues reaching ₹233 crore, a 15.2% year-on-year growth. This performance was supported by improved customer offtake and a strengthened presence in regulated markets. The Crop Protection segment contributed 42% to the revenue, with sales of ₹170 crore. While Own Products in this segment saw volume-led growth, the CDMO business was impacted by customer inventory adjustments and higher input costs.
Key Financial Metrics
Profit Before Tax (PBT) after exceptional items was reported at (₹10) crore for Q1 FY27, compared to (₹30) crore in Q1 FY26. The company registered a Net Profit of (₹7) crore for the quarter, an improvement from a Net Profit of (₹22) crore in the same period last year. The Earnings Per Share (EPS) stood at (₹0.6).
Operational Highlights
The company highlighted the passing of 100+ customer audits at its Bangalore facility. Business momentum is expected to strengthen throughout FY27, driven by improving demand visibility and expanding CDMO opportunities.
Source: BSE
